About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Asxl1
ASXL transcriptional regulator 1
MGI:2684063
102 phenotypes from 6 alleles in 8 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Asxl1tm1.1Iaai/Asxl1tm1.1Iaai
Tg(Mx1-cre)1Cgn/0
involves: 129S/SvEv * C57BL/6 * CBA 		abnormal myelopoiesis J:208092
decreased hemoglobin content J:208092
decreased leukocyte cell number J:208092
decreased mature B cell number J:208092
decreased monocyte cell number J:208092
decreased neutrophil cell number J:208092
extramedullary hematopoiesis J:208092
increased erythroid progenitor cell number J:208092
increased nucleated erythrocyte cell number J:208092
Asxl1tm1.1Iaai/Asxl1tm1.1Iaai
Tg(VAV1-cre)1Graf/0
involves: 129S/SvEv * C57BL/6 		abnormal definitive hematopoiesis J:208092
abnormal hematopoietic stem cell morphology J:208092
abnormal myelopoiesis J:208092
anemia J:208092
decreased bone marrow cell number J:208092
decreased hemoglobin content J:208092
decreased leukocyte cell number J:208092
decreased mature B cell number J:208092
decreased monocyte cell number J:208092
decreased neutrophil cell number J:208092
decreased splenocyte number J:208092
increased erythroid progenitor cell number J:208092
increased hematopoietic stem cell number J:208092
increased nucleated erythrocyte cell number J:208092
Asxl1tm1.1Mjxu/Asxl1+
involves: 129 * C57BL/6 		abnormal blood cell morphology/development J:208085
abnormal bone marrow cell morphology/development J:208085
abnormal common myeloid progenitor cell morphology J:208085
abnormal leukocyte morphology J:208085
abnormal liver morphology J:208085
abnormal myelopoiesis J:208085
abnormal neutrophil morphology J:208085
abnormal neutrophil physiology J:208085
abnormal spleen morphology J:208085
anemia J:208085
decreased B cell number J:208085
decreased hematopoietic stem cell number J:208085
decreased leukocyte cell number J:208085
decreased neutrophil cell number J:208085
enlarged liver J:208085
enlarged spleen J:208085
increased apoptosis J:208085
increased cell proliferation J:208085
increased hematopoietic stem cell number J:208085
increased leukemia incidence J:208085
increased leukocyte cell number J:208085
increased malignant tumor incidence J:208085
increased monocyte cell number J:208085
increased sarcoma incidence J:208085
polychromatophilia J:208085
premature death J:208085
thrombocytopenia J:208085
Asxl1tm1.1Mjxu/Asxl1tm1.1Mjxu
involves: 129 * C57BL/6 		abnormal common myeloid progenitor cell morphology J:208085
abnormal hematopoietic stem cell physiology J:208085
abnormal leukocyte morphology J:208085
abnormal megakaryocyte morphology J:208085
abnormal neutrophil morphology J:208085
abnormal spleen white pulp morphology J:208085
anemia J:208085
anophthalmia J:208085
decreased B cell number J:208085
decreased body size J:208085
decreased body weight J:208085
decreased erythroid progenitor cell number J:208085
decreased hematopoietic stem cell number J:208085
decreased leukocyte cell number J:208085
decreased lymphocyte cell number J:208085
decreased spleen red pulp amount J:208085
decreased spleen weight J:208085
impaired hematopoiesis J:208085
increased apoptosis J:208085
increased bone marrow cell number J:208085
increased cell proliferation J:208085
increased monocyte cell number J:208085
increased number of Howell-Jolly bodies J:208085
increased single-positive T cell number J:208085
lethality throughout fetal growth and development, incomplete penetrance J:208085
myeloid hyperplasia J:208085
neonatal lethality, incomplete penetrance J:208085
polychromatophilia J:208085
postnatal lethality, incomplete penetrance J:208085
premature death J:208085
small spleen J:208085
spleen atrophy J:208085
thrombocytopenia J:208085
Asxl1tm1.2Iaai/Asxl1+
involves: 129S/SvEv * C57BL/6 		abnormal craniofacial morphology J:208092
Asxl1tm1.2Iaai/Asxl1tm1.2Iaai
involves: 129S/SvEv * C57BL/6 		abnormal hyoid bone morphology J:208092
abnormal skeleton morphology J:208092
anophthalmia J:208092
cleft palate J:208092
lethality throughout fetal growth and development, complete penetrance J:208092
mandible hypoplasia J:208092
microphthalmia J:208092
vertebral transformation J:208092
Asxl1tm1a(EUCOMM)Wtsi/Asxl1+
B6Dnk;B6Brd;B6N-Asxl1tm1a(EUCOMM)Wtsi Tyrc-Brd/WtsiH 		abnormal cornea morphology J:175295
cornea opacity J:175295
decreased circulating glucose level J:175295
decreased hemoglobin content J:175295
decreased leukocyte cell number J:175295
decreased lumbar vertebrae number J:175295
decreased mean corpuscular hemoglobin J:175295
increased blood uric acid level J:175295
increased sacral vertebrae number J:175295
vertebral fusion J:175295
Asxl1tm1a(EUCOMM)Wtsi/Asxl1+
C57BL/6N-Asxl1tm1a(EUCOMM)Wtsi/Cnrm 		abnormal coping response J:165965
decreased B cell number J:165965
decreased circulating free fatty acids level J:165965
decreased circulating triglyceride level J:165965
increased circulating alkaline phosphatase level J:165965
increased circulating iron level J:165965
increased mean corpuscular hemoglobin concentration J:165965
Asxl1tm1a(EUCOMM)Wtsi/Asxl1+
involves: C57BL/6N 		eye opacity J:200082
increased opacity of vitreous body J:200082
Asxl1tm1a(EUCOMM)Wtsi/Asxl1tm1a(EUCOMM)Wtsi
involves: C57BL/6N 		lethality, complete penetrance J:200082
Asxl1tm1Bc/Asxl1tm1Bc
involves: 129P2/OlaHsd * C57BL/6J 		abnormal blood cell morphology/development J:155898
abnormal common myeloid progenitor cell morphology J:155898
abnormal immune system cell morphology J:155898
abnormal immune system organ morphology J:155898
abnormal lymphopoiesis J:155898
abnormal thymus morphology J:155898
decreased B cell number J:155898
decreased bone marrow cell number J:155898
decreased CD4-positive, alpha-beta T cell number J:155898
decreased pre-B cell number J:155898
decreased T cell number J:155898
extramedullary hematopoiesis J:155898
increased double-negative T cell number J:155898
spleen hyperplasia J:155898
Tg(Vav1-Asxl1*Y588X)#Fcy/0
C57BL/6-Tg(Vav1-Asxl1*Y588X)#Fcy 		abnormal definitive hematopoiesis J:257690
abnormal hematopoietic stem cell physiology J:257690
abnormal myeloid cell morphology J:257690
abnormal neutrophil morphology J:257690
abnormal spleen morphology J:257690
decreased body weight J:257690
decreased erythrocyte cell number J:257690
decreased hemoglobin content J:257690
decreased leukocyte cell number J:257690
decreased lymphocyte cell number J:257690
decreased megakaryocyte-erythroid progenitor cell number J:257690
enlarged spleen J:257690
hepatosplenomegaly J:257690
increased acute myeloid leukemia incidence J:257690
increased granulocyte monocyte progenitor cell number J:257690
increased hematopoietic stem cell number J:257690
increased leukocyte cell number J:257690
increased megakaryocyte cell number J:257690
increased monocyte cell number J:257690
increased myeloid cell number J:257690
increased myeloid sarcoma incidence J:257690
increased neutrophil cell number J:257690
increased number of Howell-Jolly bodies J:257690
premature death J:257690
thrombocytosis J:257690
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/19/2024
MGI 6.24 		The Jackson Laboratory